Pilar Peris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pilar Peris has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Nuria Guañabens
University of Barcelona
3 shared publicationsAna Monegal
University of Barcelona
2 shared publicationsConcepción Moll
Servicio de Reumatología, Hospital Clínic, University of Barcelona, Villarroel 170, Barcelona, Spain
2 shared publicationsM. Angeles Martínez
University of Barcelona
2 shared publicationsA Monegal
Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
1 shared publicationA. Monegal
Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS)
1 shared publication
Latest Publications
- 3 September 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (12) , 1585-1586
Vertebral “clover” scintigraphic image in a vertebral metastasis misdiagnosed with Paget’s disease
The diagnosis of Paget’s bone disease (PD) is often reached fortuitously with X-ray or scintigraphy. The peculiar distribution of the bone tracer in some skeletal locations, such as vertebra, may be highly suggestive of this disorder. Indeed, there are two distinct vertebral images on the bone scan highly specific of PD: the “clover” and the “heart” images. It has been previously reported that the specificity of these images for PD diagnosis is very high, nearly 100%, then suggesting that these findings could be patognomonic of this process. We have recently observed a 55-year-old male patient with back pain secondary to a vertebral metastasis due to a hepatocellular carcinoma. Initially, the bone scan showed the characteristic “clover” image at T-12 level and he was misdiagnosed with PD. Afterwards, the MRI suggested the diagnosis of a vertebral metastasis, and a computed tomography-guided needle biopsy further confirmed the diagnosis. In view of the present data, this image cannot be considered as patognomonic of PD.
- 3 September 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (12) , 1585-1586
Vertebral “clover” scintigraphic image in a vertebral metastasis misdiagnosed with Paget’s disease
The diagnosis of Paget’s bone disease (PD) is often reached fortuitously with X-ray or scintigraphy. The peculiar distribution of the bone tracer in some skeletal locations, such as vertebra, may be highly suggestive of this disorder. Indeed, there are two distinct vertebral images on the bone scan highly specific of PD: the “clover” and the “heart” images. It has been previously reported that the specificity of these images for PD diagnosis is very high, nearly 100%, then suggesting that these findings could be patognomonic of this process. We have recently observed a 55-year-old male patient with back pain secondary to a vertebral metastasis due to a hepatocellular carcinoma. Initially, the bone scan showed the characteristic “clover” image at T-12 level and he was misdiagnosed with PD. Afterwards, the MRI suggested the diagnosis of a vertebral metastasis, and a computed tomography-guided needle biopsy further confirmed the diagnosis. In view of the present data, this image cannot be considered as patognomonic of PD.
- 17 August 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (2) , 269-270
Severe invalidating pain syndrome associated with benznidazole therapy for Chagas’ disease
Chagas’ disease is an endemic parasitic disease and constitutes an important health problem in Latin American countries. The increasing number of immigrants from these countries has resulted in a rise in diagnosis and consequently in the treatment of this disease in developed countries not familiar with this condition. Currently, benznidazole is used for treatment of this condition. However, undesirable effects have been reported with this treatment, and there are few data about continuous long-term use of this drug. We describe a case of invalidating pain syndrome in a 31-year-old Bolivian woman with Chagas’ disease while receiving benznidazole therapy. Because of the number of cases with this condition will probably increase because of immigration, a better understanding of the side effects of the treatment of this disease is essential.
- 17 August 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (2) , 269-270
Severe invalidating pain syndrome associated with benznidazole therapy for Chagas’ disease
Chagas’ disease is an endemic parasitic disease and constitutes an important health problem in Latin American countries. The increasing number of immigrants from these countries has resulted in a rise in diagnosis and consequently in the treatment of this disease in developed countries not familiar with this condition. Currently, benznidazole is used for treatment of this condition. However, undesirable effects have been reported with this treatment, and there are few data about continuous long-term use of this drug. We describe a case of invalidating pain syndrome in a 31-year-old Bolivian woman with Chagas’ disease while receiving benznidazole therapy. Because of the number of cases with this condition will probably increase because of immigration, a better understanding of the side effects of the treatment of this disease is essential.
- 29 August 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (6) , 958-961
Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis
Idiopathic osteoporosis is a frequent cause of osteoporosis in young premenopausal women. However, there are no data about the treatment of these patients. The aim of this study was to analyse the evolution of bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis treated with a conservative approach. Retrospective study of 16 premenopausal women with idiopathic osteoporosis (aged 35.7±7 years) with a mean follow-up period of 3 years (1–6 years). BMD measurements at the lumbar spine and femoral neck were obtained in all patients at baseline and yearly (patients had one or more fragility fractures and/or a Z score <−2 in the lumbar spine or femur). Secondary causes of osteoporosis were excluded in all patients. Patients were treated with calcium and vitamin D to achieve a calcium intake of up to 1,500 mg/day and were advised to increase physical activity. A significant increase in lumbar and femoral BMD was observed after 2 and 3 years of follow-up, respectively (1.9±1.9% mean increase in lumbar spine, p= 0.021, at 2 years) (5.6±4.5% mean increase in femur, p=0.04, at 3 years). The serum total alkaline phosphatase (TAP) values increased at 2 years (122±46 vs 140±36 U/l, p=0.054). In addition, a negative correlation between baseline TAP serum values and lumbar BMD evolution at 2 years was observed (r=−0.748, p=0.013). No patient developed new skeletal fractures during the follow-up period. In young premenopausal women with idiopathic osteoporosis the conservative treatment with supplements of calcium and vitamin D associated with an increase of physical activity is associated with an increase in BMD without evidence of further skeletal fractures after more than 3 years of follow-up.
- 29 August 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (6) , 958-961
Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis
Idiopathic osteoporosis is a frequent cause of osteoporosis in young premenopausal women. However, there are no data about the treatment of these patients. The aim of this study was to analyse the evolution of bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis treated with a conservative approach. Retrospective study of 16 premenopausal women with idiopathic osteoporosis (aged 35.7±7 years) with a mean follow-up period of 3 years (1–6 years). BMD measurements at the lumbar spine and femoral neck were obtained in all patients at baseline and yearly (patients had one or more fragility fractures and/or a Z score <−2 in the lumbar spine or femur). Secondary causes of osteoporosis were excluded in all patients. Patients were treated with calcium and vitamin D to achieve a calcium intake of up to 1,500 mg/day and were advised to increase physical activity. A significant increase in lumbar and femoral BMD was observed after 2 and 3 years of follow-up, respectively (1.9±1.9% mean increase in lumbar spine, p= 0.021, at 2 years) (5.6±4.5% mean increase in femur, p=0.04, at 3 years). The serum total alkaline phosphatase (TAP) values increased at 2 years (122±46 vs 140±36 U/l, p=0.054). In addition, a negative correlation between baseline TAP serum values and lumbar BMD evolution at 2 years was observed (r=−0.748, p=0.013). No patient developed new skeletal fractures during the follow-up period. In young premenopausal women with idiopathic osteoporosis the conservative treatment with supplements of calcium and vitamin D associated with an increase of physical activity is associated with an increase in BMD without evidence of further skeletal fractures after more than 3 years of follow-up.
- 24 July 2006
- Published by Springer Nature in Calcified Tissue International
- Vol. 79 (1) , 22-26
Biochemical Response to Bisphosphonate Therapy in Pagetic Patients with Skull Involvement
The aims of this study were to compare the response to therapy in disease activity in pagetic patients with and without skull involvement and the usefulness of bone markers in the evaluation of these patients. Forty patients with Paget’s disease treated with tiludronate and 26 healthy controls were included. Serum total and bone alkaline phosphatases (TAP, BAP), procollagen I N propeptide (PINP), and urinary N- and C-terminal cross-linking telopeptides of collagen I (NTX, α-α CTX, and β-β CTX) were measured at baseline and 6 months after therapy. The extent of the disease was evaluated using the Coutris’ index. Pagetic patients were classified into three groups: patients with skull involvement (G-I, n = 12), patients without skull involvement (G-II, n = 28), and a subgroup of patients from G-II without skull involvement but with similar disease extent to G-I (G-III, n = 10). At baseline, patients from G-I showed significantly higher values in most markers compared to G-II. α-α CTX was the marker with the highest values in all groups. Moreover, monostotic patients with skull involvement showed higher serum baseline values of TAP per unit of affected area than monostotic patients without skull involvement. After therapy, the percentage of patients with markers within the normal range was lower in G-I than in G-II and G-III. In conclusion, pagetic patients with skull involvement showed a marked increase in bone turnover and a lower response to therapy.
- 24 July 2006
- Published by Springer Nature in Calcified Tissue International
- Vol. 79 (1) , 22-26
Biochemical Response to Bisphosphonate Therapy in Pagetic Patients with Skull Involvement
The aims of this study were to compare the response to therapy in disease activity in pagetic patients with and without skull involvement and the usefulness of bone markers in the evaluation of these patients. Forty patients with Paget’s disease treated with tiludronate and 26 healthy controls were included. Serum total and bone alkaline phosphatases (TAP, BAP), procollagen I N propeptide (PINP), and urinary N- and C-terminal cross-linking telopeptides of collagen I (NTX, α-α CTX, and β-β CTX) were measured at baseline and 6 months after therapy. The extent of the disease was evaluated using the Coutris’ index. Pagetic patients were classified into three groups: patients with skull involvement (G-I, n = 12), patients without skull involvement (G-II, n = 28), and a subgroup of patients from G-II without skull involvement but with similar disease extent to G-I (G-III, n = 10). At baseline, patients from G-I showed significantly higher values in most markers compared to G-II. α-α CTX was the marker with the highest values in all groups. Moreover, monostotic patients with skull involvement showed higher serum baseline values of TAP per unit of affected area than monostotic patients without skull involvement. After therapy, the percentage of patients with markers within the normal range was lower in G-I than in G-II and G-III. In conclusion, pagetic patients with skull involvement showed a marked increase in bone turnover and a lower response to therapy.
- 1 May 2006
- Published by SAGE Publications in Lupus
- Vol. 15 (5) , 304-307
Multifocal avascular necrosis after liver transplantation: an unusual presentation of the antiphospholipid syndrome
We describe the case of a 31-year old man who presented with an antiphospholipid syndrome (APS), which manifested as multifocal avascular necrosis (AVN) one year after orthotopic liver transplantation. The patient developed multiple AVN affecting hips, left knee, humerus and tarsal bones just after withdrawal of corticosteroid therapy. Three years later when lupus anticoagulant was detected, he began anticoagulant treatment and no further AVN episodes were observed. It is important to be aware of this clinical manifestation of APS, especially in these cases where it can be easily overlooked because of corticosteroid therapy.
- 1 May 2006
- Published by SAGE Publications in Lupus
- Vol. 15 (5) , 304-307
Multifocal avascular necrosis after liver transplantation: an unusual presentation of the antiphospholipid syndrome
We describe the case of a 31-year old man who presented with an antiphospholipid syndrome (APS), which manifested as multifocal avascular necrosis (AVN) one year after orthotopic liver transplantation. The patient developed multiple AVN affecting hips, left knee, humerus and tarsal bones just after withdrawal of corticosteroid therapy. Three years later when lupus anticoagulant was detected, he began anticoagulant treatment and no further AVN episodes were observed. It is important to be aware of this clinical manifestation of APS, especially in these cases where it can be easily overlooked because of corticosteroid therapy.
- 25 March 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (6) , 1017-1019
Camptocormia as a clinical manifestation of mitochondrial myopathy
Camptocormia is an unusual condition characterized by a progressive weakness of the extensor muscles of the spine that cause an involuntary truncal flexion. Occasionally, camptocormia can be the clinical manifestation of an underlying myopathy, including inflammatory or metabolic myopathies. We present a case of a 78-year-old female with camptocormia associated with a mitochondrial myopathy. Additionally, we review the clinical characteristics of three similar, previously reported cases.
- 25 March 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (6) , 1017-1019
Camptocormia as a clinical manifestation of mitochondrial myopathy
Camptocormia is an unusual condition characterized by a progressive weakness of the extensor muscles of the spine that cause an involuntary truncal flexion. Occasionally, camptocormia can be the clinical manifestation of an underlying myopathy, including inflammatory or metabolic myopathies. We present a case of a 78-year-old female with camptocormia associated with a mitochondrial myopathy. Additionally, we review the clinical characteristics of three similar, previously reported cases.
- 1 December 2003
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 17 (6) , 1043-1061
Stress fractures
- 1 December 2003
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 17 (6) , 1043-1061
Stress fractures